

Name of Journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 56229

Manuscript Type: CASE REPORT

Human epidermal growth factor receptor 2-positive colorectal cancer's response to lapatinib monotherapy: a case report

Guan JL *et al.* HER2-positive CRC response to Lapatinib Monotherapy

Ji-Lin Guan, Jian-Hua Liu, Qing Wang, Yu-Wei Cong, Yao-Xu Chen, Ke-Fei Huang, Meng-Li Huang, Ling Huang

Abstract

BACKGROUND

Match Overview

1	Internet 25 words crawled on 19-May-2020 ar.iiarjournals.org	1%
2	Internet 22 words crawled on 31-May-2018 medcraveonline.com	1%
3	Internet 22 words crawled on 26-Feb-2020 www.tandfonline.com	1%
4	Internet 21 words crawled on 23-Dec-2019 air.unimi.it	1%
5	Internet 20 words crawled on 18-Dec-2012 rgd.mcw.edu	1%
6	Internet 14 words crawled on 25-Jul-2019 academic.oup.com	1%

国内版

国际版

Serial Circulating Tumor DNA Tests to Monitor HER2-Po

4,980 Results

Any time

(PDF) Trastuzumab and pertuzumab in circulating tumor DNA ...

https://www.researchgate.net/publication/335240282...

CASE REPORT OPEN. Trastuzumab and pertuzumab in circulating tumor DNA ... tests. But now on off-label dual-anti-HER2 therapy continues to be. ... Examination of serial biopsies, circulating tumor ...

Circulating Tumor Cells and Circulating Tumor DNA ...

https://www.sciencedirect.com/science/article/pii/B9780128160619000096

Circulating Tumor DNA. Circulating tumor DNA (ctDNA) isolation, detection, and analysis have significantly improved over the past 2 decades. Several comprehensive reviews have been published.325, 331 Key studies are reviewed in this chapter. Different forms of ctDNA in several cancer types and their roles in clinical oncology also are examined.

Cited by: 4

Author: Evi Lianidou, Dave Hoon

Publish Year: 2018

Circulating Tumor Cell Isolation, Culture, and Downstream ...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971144

Pestrin M, Bessi S, Puglisi F, Minisini AM, Masci G, Battelli N, Ravaioli A, Gianni L, Di Marsico R, Tondini C. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study.

Clinical Utility of Analyzing Circulating Tumor DNA in ...

https://europepmc.org/articles/PMC6291328

Apr 26, 2018 · Treatment strategies for metastatic colorectal cancer (mCRC) are determined according to the molecular profile, which is confirmed by analyzing tumor tissue. Analysis of circulating tumor DNA (ctDNA) may overcome the limitations of tissue-based analysis by capturing spatial and temporal intratumoral heterogeneity of mCRC.

Dual-targeted therapy with trastuzumab and lapatinib in ...

https://www.researchgate.net/publication/301623909_Dual-targeted_therapy_with...

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre ...

(PDF) Development of circulating tumour DNA analysis for ...

https://www.researchgate.net/publication/338957115...

Purpose Clinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. This joint review from ASCO and the College of American Pathologists summarizes ...

Pilot Study on the Utility of Circulating HER2/Neu Levels ...

https://www.researchgate.net/publication/336172635...

Remote sampling of circulating tumor DNA can serve as viable option in clinical diagnostics. ... with a primary HER2-positive tumor. Methods: Serial measurements were taken of serum HER2, CEA, and ...

Going with the Flow: From Circulating Tumor Cells to DNA ...

https://www.researchgate.net/publication/257889181_Going_with_the_Flow_From...

Going with the Flow: From Circulating Tumor Cells to DNA. ... to both diagnose cancer and longitudinally monitor the response to medical interventions in patients with solid organ malignancies ...

Tumor Markers - Medical Clinical Policy Bulletins | Aetna

www.aetna.com/cpb/medical/data/300_399/0352.html

Tumor markers are normally produced in low quantities by cells in the body. Detection of a higher-than-normal serum level by radioimmunoassay or immunohistochemical techniques usually indicates the presence of a certain type of cancer. Currently, the main use of tumor markers is to assess a cancer's response to treatment and to check for ...

Characterization of metastatic urothelial carcinoma via ...

https://onlinelibrary.wiley.com/doi/10.1002/cncr.31314

Cell-free circulating DNA (cfDNA) NGS, also referred to as "liquid biopsy," is an attractive alternative that can provide a real-time profile of a tumor's mutational landscape in a dynamic (serial) fashion, attempting at the same time to recapitulate tumor heterogeneity and treatment resistance mechanisms.

Cited by: 22

Author: Neeraj Agarwal, Sumanta K. Pal, Andrew W...

Publish Year: 2018

1

2

3

4

5

>

Chat with Bing

Am I the most talkative search engine?

Say something...

增值电信业务经营许可证：合字B2-20090007

京ICP备10036305号

京公网安备11010802022657号

Privacy and Cookies

Legal

Advertise

Help

© 2020 Microsoft

Feedback

国内版 国际版



Human epidermal growth factor receptor 2-positive colorectal canc



ALL

IMAGES

VIDEOS

31,600 Results

Any time ▾

Human Epidermal Growth Factor Receptor 2 (HER-2/neu ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924467>

Jun 11, 2016 · **Case 1.** A 67-year-old Asian female was diagnosed with locally advanced high-grade salivary duct carcinoma in June 2011. Molecular analysis revealed **human epidermal growth factor receptor 2 (HER-2)** amplification.

Cited by: 4

Author: Daniel Sanghoon Shin, Timothy Sherry, Mic...

Publish Year: 2016

Search Tools

Turn off Hover Translation (关闭取词)

Targeting the human epidermal growth factor receptor 2 ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/29659677>

Human epidermal growth factor receptor 2 (HER2) is an oncogenic driver, and a well-established therapeutic target in breast and gastric **cancers**. Using functional and genomic analyses of patient-derived xenografts, we previously showed that a subset (approximately 5%) of metastatic **colorectal cancer** (CRC) tumors is driven by amplification or mutation of HER2.

Cited by: 54

Author: Salvatore Siena, A. Sartore-Bianchi, S. Mars...

Publish Year: 2018

A case of leptomeningeal metastases of human epidermal ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744731>

Herein, we report a case of the patient with LM from **human epidermal growth factor receptor 2 (HER2)-positive breast cancer** who responded well to **systemic chemotherapy** with lapatinib plus capecitabine.



Human epidermal growth factor receptor 2-positive colorectal canc



ALL IMAGES VIDEOS MAPS NEWS SHOPPING

29,600 Results Any time ▾

Human Epidermal Growth Factor Receptor 2 (HER-2/neu ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924467>

Jun 11, 2016 · **Case 1.** A 67-year-old Asian female was diagnosed with locally advanced high-grade salivary duct carcinoma in June 2011. Molecular analysis revealed **human epidermal growth factor receptor 2 (HER-2)** amplification.

Cited by: 4 **Author:** Daniel Sanghoon Shin, Timothy Sherry, ...

Publish Year: 2016

A case of leptomeningeal metastases of human epidermal ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744731>

Herein, we report a case of the patient with LM from **human epidermal growth factor receptor 2 (HER2)-positive breast cancer** who responded well to **systemic chemotherapy** ...

Author: Takayuki Nakao, Takeshi Okuda, Mits... **Publish Year:** 2019

Targeting the human epidermal growth factor receptor 2 ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/29659677>

Human epidermal growth factor receptor 2 (HER2) is an oncogenic driver, and a well-established therapeutic target in breast and gastric **cancers**. Using functional and genomic analyses of patient-derived xenografts, we previously showed that a subset (approximately 5%) of metastatic **colorectal cancer** (CRC) tumors is driven by amplification or mutation of HER2.

Cited by: 54 **Author:** Salvatore Siena, A. Sartore-Bianchi, S. M...

Publish Year: 2018

Targeting the human epidermal growth factor receptor 2 ...

<https://www.sciencedirect.com/science/article/pii/S0923753419345570>

May 01, 2018 · Abstract. **Human epidermal growth factor receptor 2 (HER2)** is an oncogenic driver, and a well-established therapeutic target in breast and gastric **cancers**. Using functional and genomic analyses of patient-derived xenografts, we previously showed that a subset (approximately 5%) of metastatic **colorectal cancer** (CRC) tumors is driven by amplification or mutation of HER2.

Cited by: 54 **Author:** Salvatore Siena, A. Sartore-Bianchi, S. M...

Publish Year: 2018

Epidermal growth factor receptor

Transmembrane Protein



The epidermal growth factor receptor is a transmembrane protein that is a receptor for members of the epidermal growth factor family of extracellular protein ligands.


W Wikipedia

People also search for

See all (5+)



HER2/neu



Receptor Tyrosine Kinase



Platelet-derived Growth Fa...



CD117



Beta-catenin

Data from: Wikipedia

Suggest an edit